Zheng Quan Shi Bao Wang·2026-01-21 07:10Core Insights - The collaboration between Merck and Moderna on the mRNA cancer vaccine mRNA-4157 has shown promising results, significantly reducing the risk of recurrence or death by 49% in high-risk melanoma patients when combined with the PD-1 inhibitor Keytruda [1][2] - The mRNA-4157 vaccine utilizes an innovative personalized neoantigen therapy mechanism, which designs synthetic mRNA encoding up to 34 new antigens based on the unique mutations in a patient's tumor DNA [2] - The positive results from mRNA-4157 highlight the unmet needs in cancer treatment and the potential market for mRNA cancer vaccines, which could reach hundreds of billions of dollars [4] Group 1 - The phase II clinical trial of mRNA-4157 demonstrated a sustained reduction in recurrence or death risk over five years, maintaining a 49% reduction, which supports the hypothesis of inducing durable immune responses [1][2] - Moderna plans to increase investment in cancer platforms, with the phase III trial of mRNA-4157 fully enrolled and expanding its indications beyond melanoma [2] - The combination of personalized vaccines and immune checkpoint inhibitors is viewed as a significant breakthrough in cancer treatment [1][2] Group 2 - EVM16, a personalized cancer vaccine developed by the domestic company, has entered human trials, marking a significant milestone in its development [3] - EVM16 integrates AI with mRNA technology to predict and select tumor-specific neoantigens, showing strong immune responses in preclinical studies [3][4] - The collaboration between EVM16 and PD-1 antibodies has demonstrated synergistic anti-tumor effects, providing a solid foundation for future clinical development [4] Group 3 - The mRNA cancer vaccine market is gaining traction, with analysts predicting that mRNA vaccines could become a new type of cancer immunotherapy that is widely accessible and personalized [4] - The competitive landscape for personalized cancer vaccines in China is evolving, with companies like 云顶新耀 making significant advancements [4] - As clinical data for products like EVM16 continues to emerge, the race for personalized cancer vaccines is entering a new phase [4]